• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Batroxobin Therapy for Sudden Hearing Loss Linked to Heart Attacks in Three Cases

by
November 14, 2026
in Health
Reading Time: 5 mins read
0
Batroxobin Therapy for Sudden Hearing Loss Linked to Heart Attacks in Three Cases

Batroxobin Therapy for Sudden Hearing Loss Linked to Heart Attacks in Three Cases

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A newly reported clinical case series describes three male patients treated for sudden sensorineural hearing loss who subsequently developed acute myocardial infarction following intravenous administration of the snake venom-derived enzyme batroxobin. The reports, documented by clinicians at institutions including The First Affiliated Hospital of Wenzhou Medical University, identify a temporal clustering of cardiac events occurring approximately 24 to 48 hours after the final dose of the defibrinogenating medication. Each patient exhibited a marked reduction in circulating plasma fibrinogen alongside preexisting, underlying coronary vascular abnormalities discovered during emergent cardiac catheterization. The authors emphasize that while these clinical observations point to a potential cardiovascular safety signal, an observational case series cannot establish a direct causal mechanism between defibrinogenation and acute coronary thrombosis.

Sudden sensorineural hearing loss constitutes an otologic emergency often attributed to acute microcirculatory impairment within the delicate vasculature of the inner ear. Because blood perfusion to the inner ear is critical, clinical protocols frequently incorporate rheological interventions designed to improve microvascular flow by lowering plasma viscosity. Batroxobin operates as a defibrinogenating enzyme that cleaves fibrinogen, thereby reducing circulating plasma fibrinogen concentrations and whole blood viscosity. Although published clinical studies demonstrate therapeutic benefits when batroxobin is combined with systemic glucocorticoids—particularly in individuals presenting with elevated baseline fibrinogen levels—the systemic depletion of fibrinogen significantly perturbs hemostatic equilibrium. This pharmacological disruption has the theoretical capacity to alter risks governing both severe bleeding and paradoxical thrombotic complications.

The first reported clinical course involved a 67-year-old male who was admitted with a four-day history of acute left-sided hearing loss and aural fullness, with pure-tone audiometry confirming severe sensorineural hearing loss. His inpatient medical management included intravenous methylprednisolone, neurotrophic agents, vasodilators, and batroxobin infusions dosed at 10 bathroxobin units on admission day two, followed by 5 units on day six. Routine hemostatic monitoring on day eight revealed that his plasma fibrinogen had dropped precipitously to 0.50 g/L, prompting medical staff to withhold further treatment until repeat testing the following day demonstrated a rebound to 1.17 g/L. A third dose of 5 units was then administered; however, approximately 48 hours later, the patient developed acute, severe back pain, diaphoresis, and profound ST-segment elevation on electrocardiography, confirming an acute ST-segment elevation myocardial infarction accompanied by marked troponin elevations.

Emergent coronary angiography and intravascular ultrasound in the first patient demonstrated extensive, high-grade coronary pathology, including total occlusion of both the distal left circumflex artery and proximal left anterior descending artery, an 80 percent diffuse stenosis in the left main coronary artery, and severe right coronary stenosis. Interventional cardiologists performed emergency thrombus aspiration and deployed overlapping drug-eluting stents from the left main trunk into the left anterior descending artery, successfully restoring physiological coronary flow. Despite these immediate procedural interventions, the patient developed Killip class IV acute heart failure and refractory cardiogenic shock, requiring prolonged mechanical circulatory support with an intra-aortic balloon pump and continuous renal replacement therapy over a 27-day intensive care unit stay. Although initially discharged after clinical stabilization, the patient experienced recurrent admissions for severe cardiac dysfunction and ultimately succumbed to cardiogenic shock.

The second case involved a 65-year-old male presenting with a 26-day history of right-sided sudden hearing loss, whose diagnostic pure-tone audiometry revealed mixed hearing loss featuring an extensive high-frequency sensorineural deficit. The patient received intravenous methylprednisolone, neurotrophic agents, vasodilators, and two doses of batroxobin, consisting of 10 units on hospital day one and 5 units on day four. Following this protocol, his plasma fibrinogen level experienced a steep decline from a baseline measurement of 4.46 g/L down to a nadir of 0.48 g/L. Approximately 24 hours after receiving his second batroxobin infusion, the patient developed substernal chest and abdominal burning, coupled with a dynamic rise in high-sensitivity troponin T levels that culminated in a definitive diagnosis of acute non-ST-segment elevation myocardial infarction.

Subsequent coronary angiography and intravascular ultrasound imaging performed on the second patient identified scattered atherosclerotic plaques throughout the circumflex and right coronary systems, a 70 percent stenosis at the posterior descending artery ostium, and an 80 percent stenosis in the mid-left anterior descending artery. Cross-sectional ultrasound evaluation specifically identified an unstable, vulnerable plaque with minor calcification, focal thrombosis, and a 73 percent plaque burden. The patient was successfully stabilized and treated with targeted percutaneous coronary intervention, receiving a single intracoronary stent that expanded the minimal lumen area to 9.13 square millimeters, after which he experienced an uneventful post-procedural recovery with preserved left ventricular function and remained clinically stable during follow-up visits.

In the third patient, a 41-year-old male who sought care at an external facility after experiencing left-sided hearing loss and tinnitus for four days, pure-tone audiometry identified a prominent mid-to-high frequency sensorineural impairment. He was prescribed three consecutive doses of batroxobin at 5 units every other day alongside systemic and local corticosteroids and vasodilators, notably without prior evaluation of his baseline fibrinogen concentration. On the day of his third and final infusion, he experienced transient chest tightness and mild dyspnea that initially resolved with rest. However, in the early morning hours of the subsequent day, symptoms recurred with severe diaphoresis, prompting emergency electrocardiographic evaluation that confirmed an acute inferior myocardial infarction accompanied by a suppressed fibrinogen level of 0.75 g/L and markedly elevated D-dimer levels.

Coronary angiography in the third case revealed an atypical vascular architecture comprising diffuse, multiple aneurysmal dilations affecting the circumflex and left anterior descending arteries, alongside total thrombotic occlusion of the proximal right coronary artery. Catheter-based thrombus aspiration successfully evacuated a massive intraluminal clot and restored normal anterograde blood flow without uncovering any underlying, fixed mechanical stenosis. Intravascular ultrasound subsequently confirmed minimal atherosclerotic plaque burden without structural plaque rupture. Given the presence of persistent ectatic coronary segments predisposing to localized stasis and clot formation, clinicians transitioned the patient to intensified long-term anticoagulation with rivaroxaban and clopidogrel, after which he achieved complete clinical recovery and maintained stable outpatient follow-up.

The authors analyzed the shared characteristics across the three distinct clinical presentations, highlighting that myocardial infarction uniformly transpired within a narrow window of 24 to 48 hours following the final batroxobin dose. In every instance, the ischemic event coincided with a steep drop in plasma fibrinogen concentrations, which reached profound nadirs ranging between 0.48 and 0.75 g/L. Concurrently, all three patients harbored notable underlying coronary anomalies—ranging from diffuse, multivessel calcific atherosclerosis and mechanically unstable plaques to congenital or acquired aneurysmal vessel remodeling. These preexisting anatomical vulnerabilities provided an intrinsically thrombogenic vascular substrate capable of fostering local thrombus generation, thereby presenting an essential alternative clinical explanation for the observed cardiac events.

A precise biological mechanism linking pharmacological defibrinogenation to acute coronary occlusive events remains unproven and speculative. While thrombin-like snake venom enzymes deplete systemic fibrinogen, the accompanying release of fibrin degradation products and shifts in the homeostatic balance between coagulation and fibrinolytic cascades might theoretically alter platelet reactivity or local rheology over compromised arterial endothelium. Nevertheless, the clinicians note that specific markers such as platelet activation indices, tissue plasminogen activator dynamics, endothelial functioning, and coronary vasospasm parameters were not gathered. Furthermore, the confounding effects of concurrent high-dose corticosteroids and vasoactive drugs could not be isolated, nor was genetic screening for inherited thrombophilia completed.

In evaluating the limitations of their findings, the investigating authors emphasize that a retrospective series of three patients cannot determine epidemiological incidence, demonstrate statistical causality, or definitively separate drug effects from natural coronary disease progression. Instead, the authors characterize the findings as an important hypothesis-generating safety signal intended to encourage heightened diagnostic vigilance among otolaryngologists and internal medicine specialists prescribing defibrinogenating agents. The report suggests that clinicians should routinely monitor baseline and serial fibrinogen levels, carefully re-evaluate dosing schedules when precipitous declines occur, conduct individualized cardiovascular assessments in older patients or those with existing vascular risk factors, and urgently evaluate any new ischemic symptoms, such as chest tightness or dyspnea, that arise during treatment.

Subject of Research: Cardiovascular safety signal of batroxobin therapy in patients with sudden sensorineural hearing loss

Article Title: Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction

Article References: Zhuang, X., Pan, T., Hu, K., Zhu, Q., & You, S. (2026). Case Report: A potential cardiovascular safety signal during batroxobin therapy for sudden sensorineural hearing loss: a three-case series of acute myocardial infarction. Frontiers in Cardiovascular Medicine, 13, Article 1853445. https://doi.org/10.3389/fcvm.2026.1853445

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1853445

Keywords: batroxobin, sudden sensorineural hearing loss, acute myocardial infarction, fibrinogen, defibrinogenation, cardiovascular safety, coronary angiography, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, percutaneous coronary intervention, cardiogenic shock, coronary artery disease, microcirculation, otologic emergency, atherosclerotic plaque, coronary aneurysm

News Source: Ophelia Keating. (November 14, 2026). Batroxobin Therapy for Sudden Hearing Loss Linked to Heart Attacks in Three Cases. Scienmag.

Tags: Acute Myocardial Infarctionatherosclerotic plaquebatroxobincardiogenic shockcardiovascular safetycoronary aneurysmcoronary angiographyCoronary artery diseasedefibrinogenationfibrinogenmicrocirculationnon-ST-segment elevation myocardial infarctionotologic emergencyPercutaneous Coronary InterventionST-segment elevation myocardial infarctionsudden sensorineural hearing loss
Share12Tweet7Share2ShareShareShare1

Related Posts

Somatic and Germline FAS Sequencing Improves Diagnosis in Suspected ALPS Cohort

Somatic and Germline FAS Sequencing Improves Diagnosis in Suspected ALPS Cohort

November 18, 2026
Artificial Intelligence Reshapes Echocardiography Workflows and Diagnostic Reasoning Across Clinical Practice

Artificial Intelligence Reshapes Echocardiography Workflows and Diagnostic Reasoning Across Clinical Practice

November 18, 2026

Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care

November 18, 2026

Longer EMS Response Times Do Not Increase Mortality in High-Acuity Danish Emergencies

November 18, 2026

POPULAR NEWS

  • Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    29 shares
    Share 12 Tweet 7
  • Specialists Outline Cervical Cancer Screening Principles for Resource-Limited Settings

    29 shares
    Share 12 Tweet 7
  • Modified Halpern Proximal Algorithm Solves Multi-Structured Problems in Curved Hadamard Spaces

    29 shares
    Share 12 Tweet 7
  • Machine Learning Outperforms Pharmacokinetic Models Predicting Initial Vancomycin Concentrations in Septic Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Somatic and Germline FAS Sequencing Improves Diagnosis in Suspected ALPS Cohort

Artificial Intelligence Reshapes Echocardiography Workflows and Diagnostic Reasoning Across Clinical Practice

Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.